Chronic hepatitis C, Insulin resistance and vascular disease

Current Pharmaceutical Design

Volumn 16, Issue 34, 2010, Pages 3823-3829

  Trpkovic, Andreja ^a   Stokic, Edith ^b   Radak, Djordje ^c   Gluvic, Zoran ^d   Haidara, Mohamed ^e   Mousa, Shaker ^f   Mikhailidis, Dimitri P ^g   Isenovic, Esma R ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Institute for Internal Medicine   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d University Hospital Zemun   (Serbia)

^e KING KHALID UNIVERSITY   (Saudi Arabia)

^f ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hepatitis c; Insulin resistance; Interferon a; Vascular disease

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; MEVINOLIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIOGLITAZONE; PLACEBO; RIBAVIRIN; ROSIGLITAZONE; SIMVASTATIN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOPATHOGENIC EFFECT; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME PHOSPHORYLATION; FATTY LIVER; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; TREATMENT RESPONSE; VASCULAR DISEASE; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; REVIEW;

HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; OBESITY; VASCULAR DISEASES;

EID: 79551635641     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210794455067     Document Type: Article

References (116)

1. Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Compl 2006; 20: 113-120.
2. El Barbary AM, Saad, MAE, Attia MF, et al. Thrombocytopenia in patients with chronic hepatitis C: a possible role of HCV on platelet progenitor cell maturation. Angiology 2010; 61: 304-313.
3. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451.
4. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C seropositivity and carotid artery-plaque and intima-media thickening. Lancet 2002; 359: 133-135.
5. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus core positivity and carotid atherosclerosis. Circ J 2003; 67: 26-30.
6. Boddi M, Abbate R, Chellini B, et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Digest Liver Dis 2007, 39, (Suppl 1): S55-S60.
7. Vassale C, Masini S, Bianchi F, Zucchelli CG. Evidence of association between hepatitis C seropositivity and coronary artery disease. Heart 2004; 90: 565-566.
8. Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72: 1960-1965.
9. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-232.
10. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, Petrobelli F. Carotid and femoral atherosclerosis in chronic hepatitis C: A 5-year follow-up. Angiology 2009; 59: 717-720.
11. Arcari CM, Nelson KF, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006; 43: 53-56.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
13. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ri-bavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
14. Khuroo MS, Khuroo MS, Dahab ST. Meta analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis genotype 4. Alim Pharmacol Ther 2004; 20: 931-938.
15. Honda K, Takaoka A, Taniguchi T. Type 1 interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25: 349-360.
16. Honda K, Taniguchi T. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev 2006; 6: 644-658.
17. Ihle JN. Stats-signal transducers and activators of transcription. Cell 1996; 84: 331-334.
18. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci 2000; 25: 496-502.
19. Tilg H. New insights into the mechanisms of interferon a an im-munoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 1017-1021.
20. Darnell JE. STATs and gene regulation. Science 1997; 277: 1630-1635.
21. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-87.
22. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115.
23. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
24. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005; 54: 1065-1074.
25. Athyros VG, Karagiannis A, Hatzitolios AI, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009; 25(4): 971-980.
26. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. Curr Pharm Des 2009; 15(29): 3446-3462.
27. Mason AL, Lau JY, Hoang N, et al. Association of diabetes melli-tus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
28. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
29. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-1515.
30. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34.
31. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-718.
32. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423.
33. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006; 43: 1168.
34. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008; 28: 271-277.
35. Enjoji M, Kotoh K, Kato M, et al. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int J Mol Med 2008; 22: 521-527.
36. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
37. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
38. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-576.
39. Persico M, Capasso M, Russo R, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 2008; 57: 507-515.
40. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007; 46: 1009-1015.
41. Kawaguchi T, Sata M. importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization. World J Gastroenterol 2010; 16: 1943-1952.
42. Shao RX, Zhang L, Peng LF, et al. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol 2010; 84: 6060-6069.
43. Bernsmeier C, Duong FH, Christen V, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008; 49: 429-440.
44. Georgopoulou U, Tsitoura P, Kalamvoki M, Mavromara P. The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein. Biochimie 2006; 88: 651-662.
45. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004; 126: 263-277.
46. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007; 46: 558-65.
47. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000; 19: 2638-2644.
48. Mowen KA, Tang J, Zhu W, et al. Arginine methylation of STAT1 modulates IFN alpha/beta-induced transcription. Cell 2001; 104: 731-741.
49. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009; 15: 4356-4364.
50. Knobler H, Schattner A. TNF-a, chronic hepatitis C and diabetes: a novel triade. Q J Med 2005; 98: 1-6.
51. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis-a. J Clin Invest 1994; 94: 1543-9.
52. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14: 222-231.
53. Itoh Y, Okanoue T, Ohnishi N, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis c virus infection. Am J Gastroenterol 1999; 94: 1332-1340.
54. Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-191.
55. Elsammak M, Refai W, Elsawaf A, et al. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 2005; 21: 527-534.
56. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322.
57. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
58. Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72: 1960-1965.
59. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
60. Konrad T, Zeuzem S, Toffolo G, et al. Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion 2000; 62: 52-59.
61. di Cesare E, Previti M, Russo F, et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci 1996; 41: 1672-1677.
62. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514-517.
63. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548.
64. Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994; 23: 33-36.
65. Campbell S, Mclaren EH, Danesh BJ. Rapidly reversible increase in insulin requirement with interferon. BMJ 1996; 313: 92.
66. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1996; 125: 521.
67. Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: A way out for the virus? World J Gastroenterol 2009; 15: 5014-5019.
68. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
69. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-1272.
70. Poynard T, Ratziu V, McHutchinson J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
71. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
72. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009; 16: 681-688.
73. Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
74. Lagging M, Langeland N, Pedersen C, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007; 14: 29-35.
75. Sciacqua A, Perticone M, Miceli S, et al. Endothelial dysfunction and non-alcocholic liver steatosis in hypertensive patients. Nutr Metab Cardiovasc Dis 2010; [Epub ahead of print].
76. Younossi ZM, McCullough AJ. Metabolic syndrome, nonalcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29 (Suppl 2): 3-12.
77. Blonsky JJ, Harrison SA. Review article: nonalcocholic fatty liver disease and hepatitis C virus - partners in crime. Alim Pharmacol Ther 2008; 27: 855-865.
78. Cheung O, Sanyal AJ. Hepatitis C infection and nonalcocholic fatty liver disease. Clin Liv Dis 2008; 12: 573-585.
79. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
80. Charlton MR, Pockrod PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177-1186.
81. Eguchi Y, Mizuta T, Ishibashi E, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int 2009; 29: 213-220.
82. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
83. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non response to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
84. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 2006; 55: 585.
85. Tsapas A. Therapeutics. Review: metformin does not increase risk for lactic acidosis in type 2 diabetes. Ann Intern Med 2010; 153: JC1-JC9.
86. Romero-Gómez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708.
87. de Gottardi A, Pazienza V, Pugnale P, et al. Peroxisome prolifera-tor-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Alim Pharmacol Ther 2006; 23: 107-114.
88. Overbeck K, Genne D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-a and ribavirin. J Hepatol 49; 2008: 295-298.
89. Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive pts. Hepatology 2008; 48: 383A.
90. Conjeevaram H, Burant CF, McKenna B, et al. A randomized, double-blind, placebo-controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008; 48: 384A.
91. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon a-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-454.
92. Pazienza V, Clement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171.
93. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 106-112.
94. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis-as good as it gets? N Engl J Med 2005; 352: 73-75.
95. Amemiya F, Maekawa S, Itakura Y, et al. Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis 2008; 197: 361-370.
96. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-125.
97. Delang L, Paeshuyse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 2009; 50: 6-16.
98. O'George J, Kenedi C, McHutchison J. A pilot study to assess the impact of rosuvastatin therapy on HCV RNA and lipid fractions in chronic hepatitis C patients. Gastroenterology 2007; 132: S741.
99. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008; 103: 1383-1389.
100. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat 2009; 16: 479-484.
101. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007; 45: 895-898.
102. Forde KA, Law C, O'Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009; 15: 5020-5027.
103. Mihaila R, Nedelcu L, Fratila O, et al. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology 2009; 56: 1704-1709.
104. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52(3): 864-874.
105. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-140.
106. Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-340.
107. Dreux M, Pietschmann T, Granier C, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281: 18285-18295.
108. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human he-patocytes by hepatitis C virus. J Hepatol 2007; 46: 411-419.
109. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004; 324: 450-461.
110. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000; 67: 863-876.
111. Roglans N, Sanguino E, Peris C, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyc-eride in fructose-fed rats. J Pharmacol Exp Ther 2002; 302: 232-239.
112. Seo M, Inoue I, Ikeda M, et al. Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells. PPAR Res 2008; 2008: 316306.
113. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci 2010; 55: 190-195.
114. Madhoun MF, Bader T. Statins improve ALT values in chronic hepatitis C patients with abnormal values. Dig Dis Sci 2010; 55: 870-871.
115. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopou-los EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007; 195: 7-16.
116. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and impact on cardiovascular events of long-term statin treatment in patients with coronary heart disease and abnormal liver tests: a post hoc analysis of the GREACE Study. Lancet 2010; in press.